Gensight Biologics SA Asset Resilience Ratio
Gensight Biologics SA asset resilience ratio. Gensight Biologics SA (SIGHT) has an Asset Resilience Ratio of 59.58% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Gensight Biologics SA to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gensight Biologics SA (2014–2021)
Asset resilience ratio of Gensight Biologics SA from 2014 to 2021. This chart shows how Gensight Biologics SA's Asset Resilience Ratio has changed over time. Read total liabilities of Gensight Biologics SA for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gensight Biologics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SIGHT current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €24.15 Million | 59.58% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €24.15 Million | 59.58% |
Asset Resilience Insights
- Very High Liquidity: Gensight Biologics SA maintains exceptional liquid asset reserves at 59.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gensight Biologics SA Industry Peers by Asset Resilience Ratio
Compare Gensight Biologics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Gensight Biologics SA Asset Resilience Ratio by Year (2014–2021)
Gensight Biologics SA asset resilience ratio by year from 2014 to 2021. The table below shows the annual Asset Resilience Ratio data for Gensight Biologics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 78.18% | €44.29 Million ≈ $51.78 Million |
€56.65 Million ≈ $66.23 Million |
-1.93pp |
| 2020-12-31 | 80.11% | €37.94 Million ≈ $44.36 Million |
€47.36 Million ≈ $55.37 Million |
+20.85pp |
| 2019-12-31 | 59.26% | €19.25 Million ≈ $22.51 Million |
€32.48 Million ≈ $37.98 Million |
-11.70pp |
| 2018-12-31 | 70.96% | €26.24 Million ≈ $30.68 Million |
€36.98 Million ≈ $43.23 Million |
-18.17pp |
| 2017-12-31 | 89.13% | €55.45 Million ≈ $64.82 Million |
€62.21 Million ≈ $72.73 Million |
-2.01pp |
| 2016-12-31 | 91.14% | €53.98 Million ≈ $63.11 Million |
€59.23 Million ≈ $69.25 Million |
+81.68pp |
| 2014-12-31 | 9.46% | €1.40 Million ≈ $1.64 Million |
€14.82 Million ≈ $17.32 Million |
-- |
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more